Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

The use of genetic tests to diagnose and manage patients with myeloproliferative and myeloproliferative/myelodysplastic neoplasms, and related disorders.

Cross NCP., Godfrey AL., Cargo C., Garg M., Mead AJ., A British Society for Haematology Good Practice Paper None.

Original publication

DOI

10.1111/bjh.17766

Type

Journal article

Journal

Br J Haematol

Publication Date

11/2021

Volume

195

Pages

338 - 351

Keywords

chronic myelomonocytic leukaemia, eosinophilia, mastocytosis, myelodysplastic/myeloproliferative neoplasms, myeloproliferative neoplasms, Biological Products, Bone Marrow Examination, Calreticulin, Clone Cells, Disease Management, Exons, Forecasting, Genetic Testing, Humans, Janus Kinase 2, Molecular Diagnostic Techniques, Mutation, Missense, Myelodysplastic Syndromes, Myeloproliferative Disorders, Oncogene Proteins, Fusion, Point Mutation, Prognosis, Proto-Oncogene Proteins c-kit, Receptor, Platelet-Derived Growth Factor alpha, Receptors, Colony-Stimulating Factor, Receptors, Thrombopoietin, Severity of Illness Index, mRNA Cleavage and Polyadenylation Factors